We have used antisense phosphorothioate oligonucleotides to define the role played by proliferating cell nuclear antigen (PCNA) in neointimal accumulation of smooth muscle cells in a rat carotid artery injury model. The short-term extraluminal delivery of 250 nmol of antisense oligonucleotides, but not control oligonucleotides, immediately after arterial injury produces a 77% suppression of PCNA mRNA after 24 h and a 52% decrease in the frequency of medial smooth muscle cells expressing PCNA after 72 h. This reduction in PCNA expression is accompanied by a 59% decrease in the frequency of proliferating medial smooth muscle cells at 3 d as measured by BudR staining and an 80% decrease in neointimal accumulation assessed morphometrically at 2 wk. Thus, the expression of PCNA is required for medial smooth muscle cell growth in vivo and for neointimal formation after arterial injury. (J. Clin. Invest. 1994Invest. . 93:2351Invest. -2356
Introduction
The proliferation of smooth muscle cells in vitro is stimulated by various mitogens such as PDGF, IGF-1, basic fibroblast growth factor, EGF, IL-1, and TGF-f3 (1) (2) (3) . The binding of growth factors to specific receptors on smooth muscle cells initiates a complicated series of biochemical reactions which involve protein kinase C, receptor-linked tyrosine phosphorylation, and cAMP-dependent kinases (4) . The detailed molecular events which immediately follow receptor activation are currently under examination in many laboratories.
The various signal transduction mechanisms stimulated by the activation of different growth factor receptors are likely to intersect with a common pathway of intracellular components required for smooth muscle cell proliferation/migration. Indeed, the growth response in a number of cell types, including smooth muscle cells, to serum mitogens in vitro is suppressed by antisense oligonucleotides directed against c-myc, c-myb, proliferating cell nuclear antigen (PCNA),' cyclins, and non- 1 . Abbreviations used in this paper: PCNA, proliferating cell nuclear antigen; SV40LT-SMC, smooth muscle cell line immortalized with SV40 large T antigen. muscle myosins (5-1 1). Thus, antisense oligonucleotides are useful in defining key intracellular regulatory components which may be critical for the proliferation/migration of smooth muscle cells in vitro.
The biologic role of several growth factors has been established in vivo by suppressing the action ofthese mitogens in the rat carotid artery injury model and ascertaining the consequences of this experimental manipulation. The results obtained have lead to unexpected conclusions. The intravenous administration of polyclonal neutralizing antibody against PDGF in the above model produces a 40% reduction of neointimal smooth muscle cell accumulation which is mainly due to the suppression of cell migration ( 12) . The intravenous infusion ofpolyclonal neutralizing antibody against basic fibroblast growth factor in the same model prevents the first wave of smooth muscle cell growth but does not affect the final extent of neointimal smooth muscle cell accumulation ( 13) .
Until recently, it has been difficult to show that intracellular regulatory components necessary for smooth muscle cell proliferation/migration in vitro are also essential for this process in vivo. This issue is of obvious importance because the characteristics of smooth muscle cells are altered in tissue culture and mitogenic factors in the in vivo setting may include components presently unknown. We have used antisense oligonucleotides to specifically inhibit the synthesis of intracellular regulatory macromolecules in the rat carotid artery model and showed that the protooncogene, c-myb, is critically involved in the proliferation/migration of smooth muscle cells in vivo ( 14) . In the present investigation, we use a similar experimental approach to . Cells were cultured in DME supplemented with 10% FBS heat inactivated at 65°C for 45 min (10% FBS-DME). Smooth muscle cells were plated at 25,000 cells/ well in a cluster 6 plate (Bellco Biotechnology, Vineland, NJ) and allowed to attach in 10% FBS-DME. The cells were then washed twice with PBS, and the medium was changed to 0.25% FBS-DME (growth arrest medium). After 96 h, the cells were shifted to 10% FBS-DME in the presence of various concentrations of antisense or control PCNA oligonucleotides. The cells were then allowed to grow for an additional 72 h, trypsinized, and counted (Coulter Corp., Hialeah, FL). All experiments were carried out in triplicate and repeated twice.
Rat injury model. Sprague-Dawley rats (average weight 360 g) were anesthetized with ketamine (40 mg/kg) and xylazine ( 10 mg/kg), and the left carotid arteries ofthe animals were isolated via a midline cervical incision. A 2F Fogarty catheter (Baxter Diagnostics, Inc.) was introduced through the left external carotid artery ofeach rat and advanced to the aortic arch; the balloon was inflated to produce moderate resistance to catheter movement and then was withdrawn gradually to the entry point. The entire procedure was repeated three times for each animal. The oligonucleotides were added at a concentration of 1 Mmol/ ml to 25% (wt/vol) solutions of Pluronic F-127 prepared as outlined by the manufacturer (BASF-Wyandotte Corp., Wyandotte, MI) and maintained at 4VC. The solutions were applied immediately to the exposed segment ofthe artery using prechilled pipettes and pipette tips. The solution was allowed to gel, the wounds were closed, and the animals were returned to their cages. In control animals, the injury was carried out as described above, but no gel was applied.
After 2 wk, the animals were killed by an overdose ofketamine and xylazine and then perfused with 150 cm3 of normal saline under a pressure of 120 mmHg. The left carotid arteries were removed, fixed in 10% formalin, and then processed for light microscopy in a standard manner. The cross sections of four separate left carotid arterial segments from each animal were examined (six cross sections, 5 gm apart for each arterial segment). Morphometric measurements were carried out by a single observer who used an automated computer-based image analysis system and was blinded to the nature of the specimen as described previously ( 16) .
RNA analysis. The animals were killed 24 h after injury, perfused with normal saline, and injured and contralateral carotid arteries were rapidly removed and snap-frozen in liquid nitrogen. The dilutions, respectively, as described previously ( 17) . The stained nuclei were counted by an investigator blinded to the nature of the specimen and were averaged for each animal. The percentage of stained nuclei (PCNA or BudR) was determined as a ratio of stained nuclei to the total number of nuclei in the section used for analysis.
In vitro migration assay. The smooth muscle cell migration assay was carried out in a modified Boyden chamber (Costar Corp., Cambridge, MA) with an 8-Mm pore size (diameter) polycarbonate filter (Costar Corp.) dividing upper and lower well chambers. Cultured SV40LT-SMC were trypsinized and suspended at a concentration of 120,000 cells/ml in DME supplemented with 0.25% FBS. A volume of 100 Ml of cell suspension (-12,000 cells) with 25 MM antisense or scrambled PCNA oligonucleotides or no oligonucleotides (control) was placed in an upper chamber, and 1.2 ml of DME supplemented with 10% FBS was placed in the lower chamber. After 6 h ofincubation at 370C in 5% C02-supplemented room air atmosphere, the filter was removed from the chamber, and the number of cells attached to the lower surface of the filter was determined by averaging the number of cells present in five high power fields. This assay system is virtually identical to that used by other investigators to document the action of antisense c-myc oligonucleotides on chemotaxis (8) . Each assay was carried out in duplicate, and the experiments were repeated twice. The results are given as percentage of control±SD.
Results
We have used antisense oligonucleotides to PCNA to define the role played by this cell cycle-dependent protein in neointimal smooth muscle cell accumulation in a rat carotid artery injury model. The effect of antisense oligonucleotides in suppressing smooth muscle cell proliferation was tested initially in vitro. The antisense 1 PCNA oligonucleotide produced dose-dependent inhibition of the growth of SV40LT-SMC, while sense 1 control oligonucleotide had no significant effect on cell proliferation (Fig. 1) . These data are virtually identical to those reported previously by others for primary vascular smooth muscle cells ( 11 ) . We also examined the effect of antisense PCNA oligonucleotides on smooth muscle cell migration in an in vitro assay (Boyden chamber). The addition of25 MM antisense 1 or sense 1 control oligonucleotides did not influence the number of migrating cells after 6 h of exposure (80±8.7% of control vs 88±6. 1% of control, P = NS).
Given the inhibition ofsmooth muscle cell proliferation by antisense PCNA oligonucleotide in vitro, we next ascertained the action oftwo nonoverlapping antisense PCNA oligonucleotides on neointimal accumulation in a rat carotid artery injury model. To this end, the left common carotid artery of rats was subjected to balloon angioplasty, which initiates a highly reproducible intimal proliferation/migration ofsmooth muscle cells over the entire length ofthe effected blood vessel. The antisense oligonucleotides or the sense or scrambled control oligonucleotides were added to pluronic solutions at 1 mmol/ml. After balloon angioplasty, 250 Ml ofsolution (250 nmol ofoligonucle.' otide) was applied to the injured carotid artery in the neck. On contact with the artery, the solution gelled immediately, generating a translucent layer which enveloped the treated region. The wounds were closed after application of the gel, and the rats were returned to their cages. As noted previously, the pluronic gel is no longer visible 1-2 h after application.
To assess the efficacy of oligonucleotide-induced suppression of PCNA message, we killed at 24 h two animals treated with antisense 1 PCNA oligonucleotide and two animals treated with sense 1 control oligonucleotide. RNA analysis revealed significantly decreased amounts ofPCNA mRNA in the antisense oligonucleotide-treated animals as compared with The initial wave of medial smooth muscle proliferation peaks at 72 h after balloon angioplasty in the rat carotid artery injury model (18) . Given the effective suppression of PCNA message at 24 h, we then investigated the action of antisense 1 PCNA oligonucleotides, as compared with sense 1 control oligonucleotides, on the first wave of medial smooth muscle cell growth. Immunocytochemical analyses showed a 59% reduction in the frequency of medial smooth muscle cells labeled with a single injection of BudR 1 h before killing in antisense oligonucleotide-treated animals (n = 3) as compared with sense oligonucleotide-treated controls (n = 3) (Fig. 3) . To ensure representative selection of data, we examined six 5-,um sections from two different arterial segments in each animal. The magnitude of medial smooth muscle cell labeling in con- 
unpublished observations).
We also obtained additional evidence to show that the inhibitory effect of antisense PCNA oligonucleotides is due to suppression of this cell cycle-dependent gene product. In this situation, one might observe a parallel reduction of PCNA expression and BudR staining in medial smooth muscle cells after arterial injury. The above result should not be expected if the antisense oligonucleotide inhibited PCNA expression without a subsequent effect on smooth muscle proliferation and suppressed cell growth by an independent mechanism. Therefore, we determined the frequency of PCNA expression in medial smooth muscle cells 72 h after arterial injury in six animals. Immunocytochemical analysis revealed a 52% reduction in the frequency of medial smooth muscle cells expressing PCNA in antisense oligonucleotide-treated animals (n = 3) as compared with control oligonucleotide-treated animals (n = 3) (Fig. 3) . There was little difference in the spatial distribution of stained nuclei from different arterial segments of the same animal. These data are virtually identical to the frequency of medial smooth muscle cells staining with BudR at the same point in time (Fig. 3) .
Given the above sequence-specific suppression of PCNA mRNA/protein as well as the reduction in the first wave of smooth muscle cell proliferation, we then assessed the effect of oligonucleotide treatment on neointimal accumulation 2 wk after arterial injury. The administration of antisense PCNA (n = 14), but not control oligonucleotides (n = 8), produced a marked decrease in neointimal formation (Fig. 4) . No significant difference in inhibitory activity was noted with the two nonoverlapping antisense oligonucleotides (the ratios of intimal to medial cross-sectional areas for antisense 1 and anti- 
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(the ratios ofintimal to medial cross-sectional areas for sense 1 control and scrambled 2 control are 0.86±0.16, n = 5 and 1.01±0.18, n = 3, respectively). Therefore, the above data were combined into antisense PCNA oligonucleotide-treated and control oligonucleotide-treated groups. The animals treated with antisense PCNA oligonucleotides exhibit an 80% reduction in neointimal area as compared with those treated with control oligonucleotides or those undergoing balloon injury only (Fig. 5 A) . The antisense PCNA oligonucleotide, control oligonucleotide, and untreated groups ofanimals were indistinguishable with regard to medial area. The animals treated with antisense PCNA oligonucleotide exhibit an 84% reduction in the ratio of intima/media cross-sectional areas as compared with those treated with control oligonucleotides or those subjected to balloon injury only (Fig. 5 B) . To determine the likelihood of further intimal proliferation at this point in time, we carried out immunocytochemical staining for PCNA in three antisense oligonucleotide-treated rats and in three control oligonucleotide-treated rats. In both sets of animals, there was only minimal PCNA staining (< 1% ofthe cells), indicating a drop ofPCNA levels in controls and a further decline ofPCNA expression in antisense-treated rats.
Discussion
We have demonstrated previously that inhibiting the expression of the protooncogene, c-myb, arrests smooth muscle cell growth in vitro and suppresses neointimal smooth muscle cell accumulation in vivo in the rat carotid artery injury model ( 14) . These data suggest that the above protooncogene is a member of the common pathway of intracellular components used by mitogens to facilitate smooth muscle cell proliferation / migration in vivo. The role played by c-myb in smooth muscle proliferation/migration is not understood completely, but the protooncogene appears to be involved in regulating the GI /S phase transition, possibly by initiating an elevation of calcium ion at this stage ofthe cell cycle ( 19, 20) . In fibroblast cell lines, constitutive overexpression of c-myb posttranscriptionally elevates the levels of PCNA, suggesting that this cell cycle-dependent protein may be a critical link between c-myb and proliferation/migration of various cell types (21 ) .
AS PCNA (Fig. 5 A) of the intimal (black bars) and medial (stippled bars) regions of rat carotid arteries that were treated with a pluronic gel that contained 250 nmol of antisense 1 (n = 8) or antisense 2 (n = 6) oligonucleotide (AS PCNA) or a pluronic gel that contained 250 nmol of sense 1 (n = 5) or scrambled 2 (n = 3) oligonucleotide (SCR PCNA) or were untreated (Control). B depicts the ratios of intima to media in the same groups of animals.
The data are displayed as mean±SD. *P < 0.01.
PCNA was described originally as a nuclear antigen but was identified later as an auxiliary subunit of DNA polymerase (22) (23) (24) We note a small discrepancy in antisense PCNA-treated animals with regard to the 77% reduction in PCNA message at 24 h and the 52% reduction in the number of anti-PCNA antibody-stained cells at 72 h as compared with the 80% suppression of neointimal formation at 14 d. These minor discrepancies may be because ofthe lack ofa linear relationship between the frequency of anti-PCNA antibody-staining cells, the amount of PCNA protein in cells, and the ability of cells to proliferate. Alternatively, the small differences between the effect ofantisense PCNA oligonucleotides on smooth muscle cell proliferation at 72 h, as measured by staining of cells for BudR and PCNA, and neointimal formation at 14 d could indicate that smooth muscle cell migration may also be affected by this treatment. To evaluate this possibility, we carried out in vitro motility experiments with Boyden chambers and were unable to document any effect ofantisense PCNA oligonucleotides on smooth muscle cell migration. Finally, the discrepancy between these two sets ofdata may indicate that a moderate inhibition of medial smooth muscle cell proliferation during the first 3 d after injury is sufficient to produce a more profound subsequent decrease in smooth muscle cell growth and/or matrix production leading to a major decrease in neointimal formation at a later point in time. This observation is supported further by the fact that neointimal and medial cell PCNA levels declined further in both control and antisense oligonucleotidetreated animals, reaching essentially undetectable levels, suggesting that further escape from proliferation arrest in antisense-treated animals is unlikely at this point. This is consistent with the findings of Morishita et al. (26) who showed no change in neointimal formation after antisense cdc2 kinase/ PCNA treatment when observation was extended from 2 to 8 wk.
The use of antisense oligonucleotides to delineate the biologic function of specific macromolecules is sometimes criticized because of potential side effects such as cleavage of homologous mRNAs, nonspecific sequence-dependent effects of oligonucleotides, or the activation of p68 kinase by cDNA/ mRNA hybrids (27, 28) . To exclude these possibilities, we used two nonoverlapping PCNA antisense oligonucleotides as well as scrambled and sense control oligonucleotides. The proliferation ofvascular smooth muscle cells is responsible for postangioplasty coronary artery restenosis, the failure of coronary and peripheral arterial bypass grafts, and the diffuse narrowing of coronary arteries after cardiac transplantation (29, 30) . A similar pathologic process probably underlies development of atherosclerosis and hypertension (31 
